Signifor patents expiration

Can you believe SIGNIFOR received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8299209 RECORDATI RARE Pharmaceutical composition comprising cyclic somatostatin analogues
Dec, 2025

(2 years from now)

US7473761 RECORDATI RARE Somatostatin analogues
Dec, 2026

(3 years from now)

Signifor is owned by Recordati Rare.

Signifor contains Pasireotide Diaspartate.

Signifor has a total of 2 drug patents out of which 0 drug patents have expired.

Signifor was authorised for market use on 14 December, 2012.

Signifor is available in solution;subcutaneous dosage forms.

The generics of Signifor are possible to be released after 14 December, 2026.

Drugs and Companies using PASIREOTIDE DIASPARTATE ingredient

Market Authorisation Date: 14 December, 2012

Treatment: NA


More Information on Dosage

SIGNIFOR family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic